The finding that DAS change within the first months is related to achieving SDFR, suggests that biological pathways relevant for SDFR development evolve in the earliest phase after diagnosis and treatment initiation in ACPA-negative RA. Here, PRTN3 is linked to rheumatoid arthritis.